Production technologies for monoclonal antibodies and their fragments.
In recent years, monoclonal antibodies have emerged as an increasingly important class of human therapeutics. A variety of forms of antibodies, including fragments such as Fabs, Fab'2s and single-chain Fvs, are also being evaluated for a range of different purposes. A variety of expression systems and improvements within these systems have been developed to address these growing and diverse needs.
Andersen
Dana C
DC
Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA. andersen.dana@gene.com
Reilly
Dorothea E
DE
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000627:therapeutic use; D002460:Cell Line; D002468:Cell Physiological Phenomena; D004926:Escherichia coli / Q000276:immunology; D005658:Fungi / Q000276:immunology; D006801:Humans; D007128:Immunoglobulin Fragments / Q000096:biosynthesis* / Q000627:therapeutic use; D007167:Immunotherapy; D010944:Plants / Q000276:immunology
D000911:Antibodies, Monoclonal; D007128:Immunoglobulin Fragments